SGS expands testing capabilities at its Glasgow facility

29 Jan 2019

Clients will benefit from a fully comprehensive range of validated biosafety methods to support cell bank and viral vaccine manufacturing and lot release of drug product.

SGS has invested £7.6 million in its facility in Glasgow, UK to expand the capabilities and capacity for testing cell banks and routine bulk harvest for vaccines, gene and cell therapies, monoclonal antibodies and other recombinant protein-based biological medicines. The investment has been supported in part by a Scottish Enterprise Research and Development grant award of £1.7 million.

SGS expands testing capabilities at its Glasgow facility

The new laboratory has added an additional 1,200 m2 to the existing facility and will be adjacent to SGS’s existing global center of excellence for cell banks and viral vaccine biosafety.

The facility now totals 2,400 m2, employs 65 staff and plans to significantly increase the number of scientific and quality personnel at the site. Clients will benefit from a fully comprehensive range of validated biosafety methods to support cell bank and viral vaccine manufacturing and lot release of drug product, as well as new technologies for pathogen detection, including next-generation nucleic acid sequencing and new cell-based viral detection systems. The new laboratory will also increase the capacity of all existing biosafety services and enhanced real-time polymerase chain reaction (PCR) platforms, to support viral safety and genetic stability assessment of cell banks for vaccines, gene and cell therapies.

In addition, in accordance with the requirements of the US and European Pharmacopeia, SGS will undertake the development and validation of new cell-based viral detection systems at the site.

“As the pharmaceutical industry becomes increasingly focused on large molecule biologics, vaccines, gene and cell therapies, SGS continues to increase its service capacity and capabilities in this area,” commented Archie Lovatt, Scientific Director. “This is a rapidly expanding field, where much broader and highly specialized testing expertise and equipment are required to establish and ensure the safety of novel human therapies and vaccines, and one that SGS sees as key to its strategic growth.”

Julia Brown, Director for High Value Manufacturing and Health at Scottish Enterprise, added: “This investment from SGS is testament to the strength of our life sciences sector, as well as an endorsement of the wealth of talent and skills we have to offer. This expansion is great news for Scotland, creating further high-value employment in Glasgow, as well as positioning SGS Vitrology for future growth.”

Read More

Related news

Pharmapack Europe 2019 Award Winners

Pharmapack Europe 2019 Award Winners

7 Feb 2019

Awards showcased a wide range of industry-changing discoveries in drug delivery, packaging and automation.

Read more 
Brexit - the EU FMD's painful problem

Brexit - the EU FMD's painful problem

7 Feb 2019

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

Read more 
New series of advanced freeze dryers

New series of advanced freeze dryers

6 Feb 2019

The LyoConstellation series allows the development of highly aggressive cycles and the mapping of the furthest reaches of theoretical design space for a formulation.

Read more 
Hitachi Chemical to acquire apceth Biopharma

Hitachi Chemical to acquire apceth Biopharma

5 Feb 2019

Acquisition will strengthen Hitachi's presence in the second-largest cell and gene therapy market in the world.

Read more 
FDA approves first generic Advair Diskus

FDA approves first generic Advair Diskus

4 Feb 2019

Mylan's Wixela Inhub is the first FDA-approved therapeutically equivalent generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or COPD.

Read more 
Sartorius joins the community of the National Institute for Innovation in Manufacturing Biopharmaceuticals

Sartorius joins the community of the National Institute for Innovation in Manufacturing Biopharmaceuticals

3 Feb 2019

Company hopes to contribute substantially to further optimizing and accelerating the current manufacturing processes in the biopharmaceutical industry.

Read more 
Particle Sciences partners with Encube Ethicals to develop novel vaginal rings

Particle Sciences partners with Encube Ethicals to develop novel vaginal rings

31 Jan 2019

The partnership will focus on rings for the administration of existing approved drugs, improving drug effectiveness and patient compliance.

Read more 
Manufacturing consultancy up 150% as life sciences prepare for a digital future

Manufacturing consultancy up 150% as life sciences prepare for a digital future

30 Jan 2019

Increasing appetite for digitised manufacturing and using data to improve GMP manufacturing.

Read more 
UK and Russia sign MoU on regulatory co-operation on medicines

UK and Russia sign MoU on regulatory co-operation on medicines

29 Jan 2019

Medicines regulators of the UK and Russian set out key principles to support their collaboration on improving public health.

Read more 
BASF and B2B Cosmetics partner to enable individualized personal care products

BASF and B2B Cosmetics partner to enable individualized personal care products

28 Jan 2019

B2B Cosmetics will contribute their Emuage technology, which has received the “Innovation Award” at the trade show Consumer Electronics Show (CES) in Las Vegas.

Read more